Rodin taps Adam Rosenberg for top post

Rodin CEO Adam Rosenberg

Cambridge, MA-based Rodin Therapeutics has recruited biotech vet Adam Rosenberg as its new CEO. Rosenberg plans to stay on as head of Teleos Therapeutics, which is in the business of doing drug discovery work for CNS diseases, until a replacement is found. Rodin is working on an HDAC2 inhibitor for Alzheimer's and other cognitive diseases. Release

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.